In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio's top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients' concerns as AI's role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: 'The good, the bad and the ugly' Mitigating financial toxicity 'better than any drug' for people with cancer Etavopivat could offer 'great benefit' in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity We'd love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.

Ver todos los episodios